Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2011

Open Access 01-12-2011 | Research

A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain

Authors: Shigeru Toda, Atsushi Sakai, Yumiko Ikeda, Atsuhiro Sakamoto, Hidenori Suzuki

Published in: Molecular Pain | Issue 1/2011

Login to get access

Abstract

Background

Local anesthetics alleviate neuropathic pain in some cases in clinical practice, and exhibit longer durations of action than those predicted on the basis of the pharmacokinetics of their blocking effects on voltage-dependent sodium channels. Therefore, local anesthetics may contribute to additional mechanisms for reversal of the sensitization of nociceptive pathways that occurs in the neuropathic pain state. In recent years, spinal glial cells, microglia and astrocytes, have been shown to play critical roles in neuropathic pain, but their participation in the analgesic effects of local anesthetics remains largely unknown.

Results

Repetitive epidural administration of ropivacaine reduced the hyperalgesia induced by chronic constrictive injury of the sciatic nerve. Concomitantly with this analgesia, ropivacaine suppressed the increases in the immunoreactivities of CD11b and glial fibrillary acidic protein in the dorsal spinal cord, as markers of activated microglia and astrocytes, respectively. In addition, epidural administration of a TrkA-IgG fusion protein that blocks the action of nerve growth factor (NGF), which was upregulated by ropivacaine in the dorsal root ganglion, prevented the inhibitory effect of ropivacaine on microglia, but not astrocytes. The blockade of NGF action also abolished the analgesic effect of ropivacaine on neuropathic pain.

Conclusions

Ropivacaine provides prolonged analgesia possibly by suppressing microglial activation in an NGF-dependent manner and astrocyte activation in an NGF-independent manner in the dorsal spinal cord. Local anesthetics, including ropivacaine, may represent a new approach for glial cell inhibition and, therefore, therapeutic strategies for neuropathic pain.
Appendix
Available only for authorised users
Literature
1.
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, et al.: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007, 132: 237–251. 10.1016/j.pain.2007.08.033PubMedCrossRef
2.
Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, Gold MS, Porreca F, Strichartz GR: The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006, 7: S1-S29. 10.1016/j.jpain.2006.01.444PubMedCrossRef
3.
Arner S, Lindblom U, Meyerson BA, Molander C: Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies. Pain 1990, 43: 287–297. 10.1016/0304-3959(90)90026-APubMedCrossRef
4.
Chaplan SR, Bach FW, Shafer SL, Yaksh TL: Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 1995, 83: 775–785. 10.1097/00000542-199510000-00017PubMedCrossRef
5.
Tian J, Gu Y, Su D, Wu Y, Wang X: Effects of intrathecal lidocaine on hyperalgesia and allodynia following chronic constriction injury in rats. Eur J Pain 2009, 13: 130–137. 10.1016/j.ejpain.2008.03.013PubMedCrossRef
6.
Muth-Selbach U, Hermanns H, Stegmann JU, Kollosche K, Freynhagen R, Bauer I, Lipfert P: Antinociceptive effects of systemic lidocaine: Involvement of the spinal glycinergic system. Eur J Pharmacol 2009, 613: 68–73. 10.1016/j.ejphar.2009.04.043PubMedCrossRef
7.
Gu YW, Su DS, Tian J, Wang XR: Attenuating phosphorylation of p38 MAPK in the activated microglia: A new mechanism for intrathecal lidocaine reversing tactile allodynia following chronic constriction injury in rats. Neurosci Lett 2008, 431: 129–134. 10.1016/j.neulet.2007.11.065PubMedCrossRef
8.
Wen YR, Suter MR, Kawasaki Y, Huang J, Pertin M, Kohno T, Berde CB, Decosterd I, Ji RR: Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology 2007, 107: 312–321. 10.1097/01.anes.0000270759.11086.e7PubMedCrossRef
9.
Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10: 1387–1394. 10.1038/nn1997PubMedCrossRef
10.
Theodosis DT, Poulain DA, Oliet SHR: Activity-dependent structural and functional plasticity of astrocyte-neuron interactions. Physiol Rev 2008, 88: 983–1008. 10.1152/physrev.00036.2007PubMedCrossRef
11.
Gao YJ, Ji RR: Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 2010, 126: 56–68. 10.1016/j.pharmthera.2010.01.002PubMedCentralPubMedCrossRef
12.
13.
Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10: 1361–1368. 10.1038/nn1992PubMedCrossRef
14.
15.
Clark AK, Gentry C, Bradbury EJ, McMahon SB, Malcangio M: Role of spinal microglia in rat models of peripheral nerve injury and inflammation. Eur J Pain 2007, 11: 223–230. 10.1016/j.ejpain.2006.02.003PubMedCrossRef
16.
Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003, 306: 624–630. 10.1124/jpet.103.052407PubMedCrossRef
17.
Sweitzer SM, DeLeo JA: The active metabolite of leflunomide, an immunosuppressive agent, reduces mechanical sensitivity in a rat mononeuropathy model. J Pain 2002, 3: 360–368. 10.1054/jpai.2002.125181PubMedCrossRef
18.
Tawfik VL, Nutile-McMenemy N, LaCroix-Fralish ML, DeLeo JA: Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 2007, 21: 238–246. 10.1016/j.bbi.2006.07.001PubMedCrossRef
19.
Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM: Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006, 27: 85–91. 10.1016/j.tips.2005.12.001PubMedCrossRef
20.
Cahill CM, Dray A, Coderre TJ: Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology 2003, 45: 543–552. 10.1016/S0028-3908(03)00192-8PubMedCrossRef
21.
Colangelo AM, Bianco MR, Vitagliano L, Cavaliere C, Cirillo G, De Gioia L, Diana D, Colombo D, Redaelli C, Zaccaro L, et al.: A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J Neurosci 2008, 28: 2698–2709. 10.1523/JNEUROSCI.5201-07.2008PubMedCrossRef
22.
Ramer MS, Priestley JV, McMahon SB: Functional regeneration of sensory axons into the adult spinal cord. Nature 2000, 403: 312–316. 10.1038/35002084PubMedCrossRef
23.
Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994, 634: 7–12. 10.1016/0006-8993(94)90252-6PubMedCrossRef
24.
Averill S, Michael GJ, Shortland PJ, Leavesley RC, King VR, Bradbury EJ, McMahon SB, Priestley JV: NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury. Eur J Neurosci 2004, 19: 1437–1445. 10.1111/j.1460-9568.2004.03241.xPubMedCrossRef
25.
Gold BG, Storm-Dickerson T, Austin DR: Regulation of the transcription factor c-JUN by nerve growth factor in adult sensory neurons. Neurosci Lett 1993, 154: 129–133. 10.1016/0304-3940(93)90188-QPubMedCrossRef
26.
Cirillo G, Cavaliere C, Bianco MR, De Simone A, Colangelo AM, Sellitti S, Alberghina L, Papa M: Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain. Cell Mol Neurobiol 2009, 30: 51–62. 10.1007/s10571-009-9430-2PubMedCrossRef
27.
Simpson D, Curran MP, Oldfield V, Keating GM: Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs 2005, 65: 2675–2717. 10.2165/00003495-200565180-00013PubMedCrossRef
28.
Kanai Y, Tateyama S, Nakamura T, Kasaba T, Takasaki M: Effects of levobupivacaine, bupivacaine, and ropivacaine on tail-flick response and motor function in rats following epidural or intrathecal administration. Reg Anesth Pain Med 1999, 24: 444–452.PubMed
29.
Zink W, Graf BM: The toxicity of local anesthetics: the place of ropivacaine and levobupivacaine. Curr Opin Anaesthesiol 2008, 21: 645–650. 10.1097/ACO.0b013e32830c214cPubMedCrossRef
30.
Sato C, Sakai A, Ikeda Y, Suzuki H, Sakamoto A: The prolonged analgesic effect of epidural ropivacaine in a rat model of neuropathic pain. Anesth Analg 2008, 106: 313–320. 10.1213/01.ane.0000296460.91012.51PubMedCrossRef
31.
Durant PAC, Yaksh TL: Epidural injections of bupivacaine, morphine, fentanyl, lofentanil, and DADL in chronically implanted rats: a pharmacologic and pathologic study. Anesthesiology 1986, 64: 43–53. 10.1097/00000542-198601000-00008PubMedCrossRef
32.
Obata H, Sakurazawa S, Kimura M, Saito S: Activation of astrocytes in the spinal cord contributes to the development of bilateral allodynia after peripheral nerve injury in rats. Brain Res 2010, 1363: 72–80. 10.1016/j.brainres.2010.09.105PubMedCrossRef
33.
Hatashita S, Sekiguchi M, Kobayashi H, Konno S, Kikuchi S: Contralateral neuropathic pain and neuropathology in dorsal root ganglion and spinal cord following hemilateral nerve injury in rats. Spine 2008, 33: 1344–1351. 10.1097/BRS.0b013e3181733188PubMedCrossRef
34.
Elkabes S, Peng L, Black IB: Lipopolysaccharide differentially regulates microglial trk receptor and neurotrophin expression. J Neurosci Res 1998, 54: 117–122. 10.1002/(SICI)1097-4547(19981001)54:1<117::AID-JNR12>3.0.CO;2-4PubMedCrossRef
35.
Nakajima K, Kikuchi Y, Ikoma E, Honda S, Ishikawa M, Liu Y, Kohsaka S: Neurotrophins regulate the function of cultured microglia. Glia 1998, 24: 272–289. 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4PubMedCrossRef
36.
Neumann H, Misgeld T, Matsumuro K, Wekerle H: Neurotrophins inhibit major histocompatibility class II inducibility of microglia: Involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci USA 1998, 95: 5779–5784. 10.1073/pnas.95.10.5779PubMedCentralPubMedCrossRef
37.
Zhang J, Geula C, Lu C, Koziel H, Hatcher LM, Roisen FJ: Neurotrophins regulate proliferation and survival of two microglial cell lines in vitro. Exp Neurol 2003, 183: 469–481. 10.1016/S0014-4886(03)00222-XPubMedCrossRef
38.
Petruska JC, Mendell LM: The many functions of nerve growth factor: multiple actions on nociceptors. Neurosci Lett 2004, 361: 168–171. 10.1016/j.neulet.2003.12.012PubMedCrossRef
39.
Aloe L, Manni L, Properzi F, De Santis S, Fiore M: Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 2000, 86: 84–93. 10.1016/S1566-0702(00)00247-2PubMedCrossRef
40.
Leffler A, Cummins TR, Dib-Hajj SD, Hormuzdiar WN, Black JA, Waxman SG: GDNF and NGF reverse changes in repriming of TTX-sensitive Na + currents following axotomy of dorsal root ganglion neurons. J Neurophysiol 2002, 88: 650–658.PubMed
41.
Tang XQ, Cai J, Nelson KD, Peng XJ, Smith GM: Functional repair after dorsal root rhizotomy using nerve conduits and neurotrophic molecules. Eur J Neurosci 2004, 20: 1211–1218. 10.1111/j.1460-9568.2004.03595.xPubMedCrossRef
42.
Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LDF, Thompson SWN, Marchand F, McMahon SB: CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain 2009, 13: 263–272. 10.1016/j.ejpain.2008.04.017PubMedCrossRef
43.
Zhang J, De Koninck YD: Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 2006, 97: 772–783. 10.1111/j.1471-4159.2006.03746.xPubMedCrossRef
44.
Mika J, Korostynski M, Kaminska D, Wawrzczak-Bargiela A, Osikowicz M, Makuch W, Przewlocki R, Przewlocka B: Interleukin-1alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain 2008, 138: 587–597. 10.1016/j.pain.2008.02.015PubMedCrossRef
45.
Zhou Z, Peng X, Hao S, Fink DJ, Mata M: HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor α in spinal cord microglia. Gene Ther 2008, 15: 183–190. 10.1038/sj.gt.3303054PubMedCentralPubMedCrossRef
46.
Malcangio M, Ramer MS, Boucher TJ, McMahon SB: Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord. Eur J Neurosci 2000, 12: 139–144. 10.1046/j.1460-9568.2000.00890.xPubMedCrossRef
47.
Mitchell VA, White DM, Cousins MJ: The long-term effect of epidural administration of butamben suspension on nerve injury-induced allodynia in rats. Anesth Analg 1999, 89: 989–994. 10.1097/00000539-199910000-00031PubMed
48.
Shin JW, Pancaro C, Wang CF, Gerner P: Low-dose systemic bupivacaine prevents the development of allodynia after thoracotomy in rats. Anesth Analg 2008, 107: 1587–1591. 10.1213/ane.0b013e31818200aaPubMedCrossRef
49.
Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16: 109–110. 10.1016/0304-3959(83)90201-4PubMedCrossRef
50.
Bennett GJ, Xie YK: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33: 87–107. 10.1016/0304-3959(88)90209-6PubMedCrossRef
51.
Størkson RV, Kjørsvik A, Tjølsen A, Hole K: Lumbar catheterization of the spinal subarachnoid space in the rat. J Neurosci Methods 1996, 65: 167–172.PubMedCrossRef
52.
Nagano M, Suzuki H: Quantitative analyses of expression of GDNF and neurotrophins during postnatal development in rat skeletal muscles. Neurosci Res 2003, 45: 391–399. 10.1016/S0168-0102(03)00010-5PubMedCrossRef
53.
Wei XY, Zhao CH, Liu YY, Wang YZ, Ju G: Immuohistochemical markers for pituicyte. Neurosci Lett 2009, 465: 27–30. 10.1016/j.neulet.2009.06.059PubMedCrossRef
Metadata
Title
A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain
Authors
Shigeru Toda
Atsushi Sakai
Yumiko Ikeda
Atsuhiro Sakamoto
Hidenori Suzuki
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2011
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-7-2

Other articles of this Issue 1/2011

Molecular Pain 1/2011 Go to the issue

Research

Expression of the dopaminergic D1 and D2 receptors in the anterior cingulate cortex in a model of neuropathic pain

Research

Cannabinoid CB2 Receptors Contribute to Upregulation of β-endorphin in Inflamed Skin Tissues by Electroacupuncture

Short report

Hypotonicity modulates tetrodotoxin-sensitive sodium current in trigeminal ganglion neurons

Research

Lentiviral gene transfer into the dorsal root ganglion of adult rats

Research

Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice

Research

Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants